|
||||||||
Part of: Jaber SA, Saadh M (2023) Comparison of the efficacy of one, two, and third doses of BNT162b2 in patients suffering from cardiovascular diseases, respiratory diseases, and diabetes against COVID-19. Pharmacia 70(1): 155-159. https://doi.org/10.3897/pharmacia.70.e97777 |